April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Vitreous Protein Profiles During the Second Trimester of Human Embryogenesis
Author Affiliations & Notes
  • J. Sebag
    VMR Institute, University of Southern California, Huntington Beach, California
  • M. Madigan
    Save Sight Institute, University of Sydney, Sydney, Australia
  • E. Feener
    Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
  • M. Niemeyer
    Heidelberg University, Heidelberg, Germany
  • B. Gao
    Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
  • L. P. Aiello
    Beetham Eye Institute, Joslin Diabetes Center and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • A. A. Sadun
    Doheny Eye Institute, Keck-USC School of Medicine, Los Angeles, California
  • J. M. Provis
    Australian National University, ANU Medical School, Canberra, Australia
  • Footnotes
    Commercial Relationships  J. Sebag, None; M. Madigan, None; E. Feener, None; M. Niemeyer, None; B. Gao, None; L.P. Aiello, None; A.A. Sadun, None; J.M. Provis, None.
  • Footnotes
    Support  VMR Consulting, Inc.;Massachusetts Lions Eye Research; ARC Centre for Vision Science Excellence ANU
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5342. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Sebag, M. Madigan, E. Feener, M. Niemeyer, B. Gao, L. P. Aiello, A. A. Sadun, J. M. Provis; Vitreous Protein Profiles During the Second Trimester of Human Embryogenesis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5342.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The vascular primary vitreous undergoes regression of the hyaloid vasculature during the second trimester of gestation. Using proteomic analyses of individual vitreous samples (vitreomics), the human vitreous protein profile was determined at various times during the 4th and 5th months of gestation.

Methods: : 12 eyes from human embryos aged 14 to 20 weeks of gestation were dissected in the fresh state and vitreous samples were immediately frozen at -80 C. Proteomic analysis was performed in each individual vitreous sample with one-dimensional SDS-PAGE and nano-LC tandem mass spectrometry. Results were compared between early 2nd trimester (week 14 to 17.5, N=4), and late 2nd trimester (week 18.5 to 20, N=8) using Student's T-test.

Results: : There were statistically significant decreases in one protein and increases in the concentrations of 6 protein precursors. Profilin-1 decreased 2.1 fold (P=0.02). Cadherin-2 increased 2.7-fold (P=0.005), Clusterin increased 1.8-fold (P=0.04), Cystatin-C increased 3.7-fold (P=0.0005), Dystroglycan increased 2.2-fold (P=0.002), Glypican-2 increased 2.9-fold (P=0.01), and Pigment Epithelium-Derived Factor (PEDF) increased 3-fold (P=0.002) when comparing early and late 2nd trimester human vitreous.

Conclusions: : Concurrent with the period of hyaloid vaessel regression, there was a significant decrease in Profilin-1 (actin binding protein) and an increase in Cadherin (cell adhesion protein), Clusterin (apolipoprotein), Cystatin-C (protease inhibitor), Dystroglycan (cell surface protein), Glypican (cell adhesion), and PEDF (angio-inhibitory) precursors during the second trimester of human embryogenesis. PEDF and Clusterin are known to have anti-angiogenic properties that could contribute to vessel regression. Profilin-1 is required for capillary morphogenesis (Exp Cell Res 2009;315:2963-73) and it's decline in late 2nd trimester may also contribute to hyaloid vascular regression. Further vitreomic study is needed to determine the potential role of these factors in regression of the fetal hyaloid vasculature and their potential usefulness as novel therapeutics.

Keywords: vitreous • development • proteomics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×